UPCC 45419: Phase I Study of Tasquinimod Alone and in Combination with Standard Therapy for Relapsed or Refractory Myeloma
Recruiting
99 years or below
All
Phase
1
54 participants needed
1 Location
Brief description of study
The research study is being conducted to understand the effects of tasquinimod, an experimental medication, on patients with myeloma. Eligibile subject have multiple myeloma that has been previously treated and is now in need of additional treatment. Part 1 of this study evaluates tasquinimod alone. Part 2 of this study evaluates tasquinimod in combination with a standard myeloma treatment regimen known as IRd (including ixazomib, lenalidomide, and dexamethasone).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
09 Apr 2021.
Study ID: 842603
